ABCELLERA BIOLOGICS INC (ABCL) Stock Analyst Ratings
NASDAQ:ABCL - Nasdaq - CA00288U1066 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to ABCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.39. This target is 308.77% above the current price.
ABCL was analyzed by 15 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ABCL.
In the previous month the buy percentage consensus was at a similar level.
ABCL was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-11-05 | Benchmark | Reiterate | Hold |
| 2024-11-05 | Stifel | Reiterate | Buy -> Buy |
| 2024-08-20 | Benchmark | Downgrade | Buy -> Hold |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-05-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-22 | Benchmark | Upgrade | Hold -> Buy |
| 2024-02-21 | Stifel | Maintains | Buy -> Buy |
| 2023-12-05 | Keybanc | Initiate | Overweight |
| 2023-08-31 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-28 | Cowen & Co. | Initiate | Outperform |
| 2023-02-22 | BMO Capital | Maintains | Outperform |
| 2023-02-22 | Credit Suisse | Reiterate | Outperform |
| 2023-01-06 | SVB Leerink | Maintains | Outperform |
| 2022-12-15 | Goldman Sachs | Initiate | Buy |
| 2022-11-16 | Truist Securities | Initiate | Buy |
| 2022-11-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-10 | Credit Suisse | Maintains | Outperform |
| 2022-07-26 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | Piper Sandler | Maintains | Overweight |
| 2022-02-25 | SVB Leerink | Maintains | Outperform |
| 2022-02-25 | Credit Suisse | Maintains | Outperform |
| 2021-12-21 | Benchmark | Initiate | Buy |
| 2021-11-19 | Piper Sandler | Initiate | Overweight |
| 2021-08-13 | Credit Suisse | Maintains | Outperform |
| 2021-05-14 | Credit Suisse | Maintains | Outperform |
| 2021-03-30 | Stifel | Maintains | Buy |